Navigation Links
EMD Serono Named as a Top Employer by Science Magazine

- Ranked Number 7 out of top 20 Employers Across Life Sciences Industry -

ROCKLAND, Mass., Oct. 9 /PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that it has been named by Science magazine as a top employer in the biotechnology and pharmaceutical industries, ranking number 7 out of the top 20 employers across the life sciences.

"We are honored that the scientific community has recognized EMD Serono as a leading place to work," said Bernhard Kirschbaum, PhD, Executive Vice President, Research, Merck Serono. "Our success as a leader within the biopharmaceutical industry is a direct result of the hard work, passion and dedication of our employees. We are committed to creating an environment for our scientists that fosters growth, professional development and a place where intellectually curious people can thrive and grow with a common goal of finding new treatments for unmet medical needs."

This is the second time EMD Serono has been placed on Science magazine's Top Employer survey; previously the organization ranked number 17.

The survey sought to determine which biotechnology and pharmaceutical companies were most admired by people who work in the field, and why. Survey respondents also rated the companies on 23 different attributes, which included Corporate Image, Financial Prowess, Leadership and Direction, Work/Culture Environment, Location and Academic and Intellectual Challenge. The methodology used for the survey included email invitations to AAAS members, Science Careers registrants, and Science website visitors.

The ranking is a result of a survey conducted by Science magazine, along with the American Association for the Advancement of Science (AAAS), and commissioned by Senn-Delaney Culture Diagnostics and Measurement to conduct a web-based survey aimed at determining the companies in the biotechnology and pharmaceutical industries with the best reputations as employers.

About EMD Serono, Inc.

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives. The company has strong market positions in neurodegenerative diseases, with Rebif(R) (interferon beta-1a), as well as in endocrinology, with Saizen(R) (somatropin (rDNA origin) for injection), Serostim(R) (somatropin (rDNA origin) for injection) and Zorbtive(TM) (somatropin (rDNA origin) for injection). EMD Serono is a leader in fertility treatments, with Gonal-f(R) (follitropin alpha for injection), Luveris(R) (lutropin alfa for injection) and Ovidrel(R) Prefilled Syringe (choriogonadotropin alpha injection). With a clear focus on the patient and a leadership presence in the biopharmaceutical industry, EMD Serono's US footprint continues to grow, with more than 950 employees around the country and fully integrated commercial, clinical and research operations in the company's home state of Massachusetts.

For more information, please visit

About Merck KGaA

Merck is a global pharmaceutical and chemical company with total revenues of EUR 7.1 billion in 2007, a history that began in 1668, and a future shaped by 30,968 employees in 60 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

For more information, please visit or

SOURCE EMD Serono, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. EMD Serono to Adopt Revised and Strengthened PhRMA Code
2. EMD Serono Announces Planned Investment of $50 Million in Research Center in Massachusetts
3. Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device
4. ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
5. Fujirebio Diagnostics Named One of the Best Places to Work in Pennsylvania
6. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
7. Stem Cell Transplantation Program at Hackensack University Medical Center: First in Nation to Receive Joint Commission Certification for Quality and First in New Jersey to be Named a Blue Distinction(R) Center for Specialty Care.
8. Kendle Named to FORTUNE List of 100 Fastest-Growing Companies for 2008
9. Animetrics Inc. Named One of Business NH Magazine's '10 Companies to Watch' for its Significant Revenue Growth
10. Guillermo Moreno Named Aurillions Vice President of Sales and Marketing
11. NovaVision CEO Named Presenter at the AdvaMed 2008 Conference
Post Your Comments:
(Date:10/8/2015)... 2015  Today the Wyss Institute for Biologically Inspired ... start-up company Opsonix Inc. The announcement follows ... of Technology Development (OTD) and Opsonix Inc. enabling ... clinical use. --> ... people every year in the U.S. — more than ...
(Date:10/7/2015)... , October 8, 2015 ... Medical biotechnology accounts for largest bioinformatics ... bioinformatics in drug discovery and development process ... . --> ... On the basis of applications, the bioinformatics ...
(Date:10/7/2015)... 2015  ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV ) ... the development and commercialization of targeted antiviral therapies, today ... 5,000,000 shares of its common stock and warrants to ... stock at a fixed combined price to the public ... will be issued separately.  The warrants will be exercisable ...
(Date:10/7/2015)... ... October 07, 2015 , ... ... a webinar titled Smart Nanostructured Coatings to provide a comprehensive overview of the ... this free webinar at . This webinar will be given by ...
Breaking Biology Technology:
... Method Globally To The Surgical Industry. The existing face ... partial incision; however, recently highly renowned Korean cosmetic surgeon, ... lift which is a 100% non-incision method. Patients can ... without any incision done to their face. This method ...
... 8 An investor group in Trinity,Biotech plc (Nasdaq: ... manufacturer of,diagnostic products, has reconfigured the slate of replacement ... of the company,s shareholders,that the group is seeking to ... group, announced that Robert S. Winter, the founding managing ...
... Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced ... participate in a panel,discussion at the 2008 RBC Capital Marketing ... and Rheumatology", will take,place on Wednesday, December 10, 2008 at ... York City. , To ...
Cached Biology Technology:
(Date:10/7/2015)... October 8, 2015 --> ... Fingerprint Cards (FPC) during third quarter 2015 amounted to around ... around 860 MSEK that was communicated 20 August 2015. ... strengthened delivery capacity and a continued growing demand for the ... estimated to be higher than during the third quarter. The ...
(Date:10/5/2015)... , October 5, 2015 ... update for NXT-ID, Inc. (NASDAQ: NXTD ), a ... market. --> ) releases ... (NASDAQ: NXTD ), a biometric authentication company focused ... SoundView Technology Group ( ) releases ...
(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court of ... another key ruling in favor of Crossmatch ™, ... fingerprint scanner company Suprema and its U.S. partner Mentalix ... a trade provision that declares it unlawful to engage ... infringing two of Crossmatch,s patents, the 5,900,993 patent and ...
Breaking Biology News(10 mins):
... a mechanism that regulates the way an internal organelle, ... according to a report in Science Express. , ... and his colleagues at Yale study Trypanosoma brucei, the ... is exceptionally streamlined and has only one of each ...
... old. Really old, in fact, which comes as a surprise ... growth in the world's largest tropical region. , Using radiocarbon ... found that up to half of all trees greater than ... Some of the trees, Trumbore said, are as much as ...
... starting treatment with an antidepressant medication during the fall ... fall and winter months, reports a study in the ... the Society of Biological Psychiatry, published by Elsevier, a ... first systematic studies that indicate that SAD can actually ...
Cached Biology News:
... Includes: Sufficient library for 10 separate ... independent sequences, -28 gIII Sequencing Primer ... -96 gIII Sequencing Primer (100 pmol), ... coli strain ER2738, Control target (Streptavidin) ...
... Blot Recycling Kit is effective for ... that have been developed with chemiluminescence ... It is not recommended for stripping ... as it is not possible to ...
... Immulon 2HB ELISA ... provide increased binding affinity for hydrophilic ... bottom works well for reagent injection ... Each strip accomodates ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Biology Products: